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Abstract  
Objective: To evaluate the feasibility of completing a parallel-group randomised controlled trial to 
compare usual follow-up care for women who have completed treatment for gynaecological cancer 
against a nurse-led telephone intervention, known as OPCAT-G (Optimal Personalised Care After 
Treatment – Gynaecological).  
Methods: The unblinded trial aimed to recruit patients who had completed treatment for cervical, 
endometrial, epithelial ovarian or vulval cancer within the previous three months at three North Wales 
hospitals. We randomised participants to either usual hospital-based follow-up or specialist nurse-led 
telephone education, empowerment and structured needs assessment follow up.  
The primary outcomes assessed the feasibility of running a larger trial including patient eligibility, 
recruitment and retention rates and outcome measure completion. Secondary outcomes were generic 
and health-related quality of life (QoL) and a patient self-report health service use (CSRI) data collected 
at three time points (baseline, three and six months).  
Results: Of the 58 females screened, 44 were eligible (76%) and 24 (55%) were recruited and 
randomised (12:12 to control and intervention respectively). One participant was lost to follow-up. 
Recruited participants had a mean age of 60 years (SD=11.2) and were approximately five months 
from their initial diagnosis (mean=159 days, SD=58). Seventeen (71%) of participants had an 
endometrial cancer diagnosis. All outcome measures completion rates exceeded 96%. 
Although not a core feasibility objective, analyses of outcome measures indicated positive changes in 
QoL and wellbeing within the OPCAT-G group; exploratory cost consequence analysis indicated that 
the nurse-led intervention had a mean total service use cost £27 per patient (bootstrapped 95%CI: -
£290 to £240) lower than the standard care group. 
Conclusions: Eligibility, recruitment and retention rates as well as outcome measure completion 
showed that the trial is feasible. 
Trial Registration: ISRCTN45565436 DOI 10.1186/ISRCTN45565436  
Funding: Betsi Cadwaladr University Health Board (BCUHB) 
Keywords: Gynaecological cancer; follow-up; nurse-led telephone intervention; randomised 
controlled trial; quality of life; health economics; feasibility study. 
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Title: Trial of Optimal Personalised Care After Treatment – Gynaecological 
cancer (TOPCAT-G): a randomised feasibility trial 
 
 
Introduction 
There are approximately 21,000 new cases of gynaecological cancers each year in the UK and one in 
five female cancer patients have a gynaecological cancer [1](CRUK 2014). In Wales, over 1,000 women 
are diagnosed with gynaecological cancers each year [2] and in North Wales, where the feasibility 
study took place, just over 200 gynaecological cancers were newly diagnosed in 2014 [3].  
 
The follow-up care currently provided after treatment for gynaecological cancer is underpinned by a 
largely retrospective evidence-base. Furthermore, there are no guidelines from the National Institute 
for Health and Care Excellence (NICE) as to what form or frequency of follow-up is appropriate in 
relation to either effective recurrence detection or the patient’s wellbeing. The Society of Gynecologic 
Oncology recommends that there is a need for prospective research including cost-effectiveness 
calculations to help determine ideal follow-up care [4]. 
 
The most common practice is for the clinician to review a patient on a regular basis, in a hospital-
based, outpatient clinic over a number of years [5] with the aim of checking for local recurrence or 
distant metastasis [6]. However, there is no prospective evidence that the traditional method of 
follow-up identifies recurrences earlier or improves overall survival as most recurrences are 
symptomatic [7-10]. Follow-up of women with gynaecological cancer may, therefore, be accomplished 
using patient-reported outcome measures [11]. A few retrospective studies reported that survival was 
better when recurrent cervical or endometrial cancer was detected at routine follow-up rather than 
when symptoms develop [12-14], however the majority of patients relapse with symptoms that would 
prompt reassessment even if the patient was not on routine review. There is also a worry that patients 
may wait for their next routine appointment to disclose symptoms [15] thus possibly delaying 
detection and appropriate symptom management.  
 
In terms of psychological morbidity there is evidence that routine appointments can lead to high levels 
of anxiety during follow-up [16], suggesting that the patient’s psychosocial needs are not being met. 
Within the population of cancer patients, it has been shown that women have significantly higher 
levels of anxiety and depression than men [17] and furthermore, one study reported that 29% of 
gynaecological cancer patients report depressive symptoms [18]. Studies have identified that the least 
met needs of cancer outpatients typically include receiving more information on genetic issues, 
lifestyle changes, worries regarding spread or recurrences -and parking near the treatment centres 
[19]. Furthermore, some patients have requested alternative models for follow-up [20].  
 
With the lack of evidence to support medical-led hospital-based follow-up as an effective model for 
earlier detection of recurrence with improved outcome, and to address the anxiety associated with 
scheduled appointments we propose an alternative approach. This is to provide nurse-led telephone 
follow-up care for patients after treatment (OPCAT-G; Optimal Personalised Care After Treatment – 
Gynaecological). The long-term aim is to develop a national, multicentre, randomised study that will 
determine the effectiveness of this new approach in terms of health economics, quality of life (QoL), 
patient autonomy and survival for patients who have had treatment for gynaecological cancer. The 
current feasibility study is designed to determine the ability to conduct a large trial according to the 
suggested protocol.   
Materials and methods 
The feasibility of completing a randomised controlled trial (RCT) on nurse-led telephone follow-up in 
the gynaecology cancer setting (OPCAT-G) has been assessed in terms of several specific objectives: 
eligibility, recruitment, and retention rates of patients to the trial, along with completion rates of 
outcome measures. Secondary aims were to gain details to inform the design of a future trial by 
completing a process evaluation, an exploratory analysis to evaluate effect sizes and an exploratory 
cost consequence analysis. 
 
This parallel-group randomised controlled feasibility trial compared OPCAT-G (intervention arm) with 
standard care (control arm). Participants were randomised, using dynamic allocation to balance for 
the numbers of each cancer type that occur in the recruited population [21], on a 1:1 basis using site 
(three hospital sites) and disease type (endometrial, ovarian, cervical and vulva) as stratification 
variables. A full description of the trial design is detailed within the published protocol paper [22]. 
 
Inclusion criteria for participation in the study were:  
i. the patient had completed treatment for cervical, endometrial, epithelial ovarian or 
vulval cancer, 
ii. treatment had been completed within the last three months and  
iii. in the view of the treating consultant, there was no need for continued hospital-based 
care.  
 
The exclusion criteria were: 
i. previous treatment for sarcoma, germ cell tumour, borderline tumours, melanoma 
or choriocarcinoma as follow-up schedules usually requires a series of tests,  
ii. a need for ongoing treatment,  
iii. a lack of capacity to give informed consent and 
iv. an inability to take part in the trial (e.g. severe learning/ mental disability, severe 
mental health or hearing problems, not able to understand Welsh or English).  
 
Patients were recruited from three hospitals in North Wales, UK, by the research nurse (RN) 
and clinical nurse specialists (CNSs). Potential patients were given a participant information 
sheet at their end of treatment visit and had until their first follow-up appointment to 
consider the study (on average 56 days apart) where they gave consent and completed the 
baseline questionnaire before being randomised. 
 
The participants, RN and CNSs and trial management were unblinded during this trial. All 
other members of the team (including the research officer, chief investigators and the trial 
statistician), were blinded. The blinded members would have had access to a coded 
breakdown of treatment group assignments which was only broken post-analysis.  
  
Patients randomised to standard care continued to have their hospital-based consultant-led medical 
reviews at three and six-months post baseline and were followed-up according to an agreed protocol 
with the regional gynaecological cancer multidisciplinary team that represented current practice.  
 
Patients randomised to the OPCAT-G intervention arm received an information booklet at baseline, 
which included information on: 
i. patterns of relapse, possible warning symptoms and how to respond to these, 
ii. possible long-term physical and psychological side effects of treatment and how these can be 
managed, 
iii. how patients could contact the clinical team if they have concerns or symptoms, 
iv. treatment, diagnosis and disease-specific information, 
v. needs assessment measures made up from the Macmillan Concerns Checklist [23], 
CancerCAN-22 [19] and the Distress Thermometer [24].  
 
These participants did not attend the hospital for their follow-up appointments but instead received 
a scheduled nurse-led telephone follow-up, firstly within four weeks of randomisation and again six-
months post baseline. Patients were asked to complete the needs assessment measures prior to each 
scheduled telephone call to inform a structured discussion with the CNS. Any issues identified in these 
calls were referred to the most appropriate source of help. Additional phone calls could be instigated 
at any time by the patient, where their completed needs assessments would be discussed as with 
scheduled calls.  
 
A process evaluation was included to reflect upon the recruitment strategy of the trial and explain any 
differences present between the recruiting sites. Assessment of key variables that influenced 
recruitment to this feasibility trial should facilitate improved recruitment into a future RCT. All of the 
nurses (three CNSs and one RN) who were part of the trial took part in process evaluation interviews 
after the follow-up period was completed. The interviews were either face-to-face or by telephone, 
lasted 30-45 minutes (see Appendix 1 for the interview schedule) and were recorded, transcribed and 
checked afterwards.  
 
To evaluate the appropriateness of measures and potentially identify a primary outcome for a future 
RCT, the following outcome measures were collected. EORTC QLQ-C30 [25], EQ-5D-3L [26], ICEpop 
CAPability measure for Adults (ICECAP-A) [27] and a Client Service Receipt Inventory (CSRI) [28, 29]. 
All outcomes were aiming to assess the QoL and wellbeing of the participants (see Appendix 2 for 
further details). All of these were completed at three time-points: baseline, three-months and six-
months post baseline. Additionally, patient demographics relating to their characteristics, cancer 
disease type and treatment were collected at baseline.  
 
The sample size was estimated based on the assumption of screening 150 patients during a 
six-month recruitment period, with approximately 30% of these being ineligible and 50% 
acceptance into the trial. This resulted in a provisional estimate of recruiting 50 patients to 
the trial.  
 
Calculating effect sizes for the relevant outcome measures was completed using analysis of 
covariance (ANCOVA) models on the six-month follow-up data adjusting for the participant’s 
baseline scores, site and disease type (stratification variables). Normality of the outcomes has 
been evaluated to ensure appropriate use of this analysis. All statistical analyses were 
undertaken using IMB SPSS Statistics 22 [30] and completed on an intention-to-treat basis. All 
analyses relating to health economics were undertaken using Microsoft Excel 2010 and IBM 
SPSS Statistics 22 [30].  
 
Ethical approval was granted for the full feasibility trial by NRES Committee London – South 
East on the 22nd May 2015 (Ref: 15/LO/0716, IRAS number: 167879). Research and 
Development (R&D) approval was granted on the 26th August 2015 by the R&D internal panel 
board, Betsi Cadwaladr University Health Board. For the additional process evaluation, ethical 
approval was granted on 7thNovember 2016 (Ref: 15/LO/0716). Local research governance 
processes were followed. 
  
Results 
Fifty-eight women were screened to take part in the study during a period of six months between 
September 2015 and February 2016. Those deemed eligible to take part in the study accounted for 
76% of the screened population (44 patients) with the main reason for ineligibility was that the patient 
required on-going hospital care (64%). Of the 44 eligible women, 24 consented to take part in the 
study, giving a recruitment rate of 55%. The main reason for non-recruitment was that patients did 
not want to be randomised (70%) and the main basis for this was due to wanting to see a doctor for 
their follow-up (10 out of 14 patients). Only one patient was lost to follow-up during the study, giving 
a retention rate of 96%. The CONSORT flowchart in Figure 1 provides a further breakdown of these 
data.  
 
The desired thresholds defined in the protocol and statistical analysis plan a priori were at least 50% 
eligibility, recruitment and retention rates. These criteria have been satisfied.  
 
All three sites within the study were successful at recruiting participants, but to varying degrees. The 
results of the process evaluation showed that the differences in recruitment success at the three trial 
sites were mainly due to the lack of early CNS involvement in the feasibility trial, lack of sufficient 
training and a lack of research network support due to the limited funding available to the feasibility 
trial. A CNS response to poor recruitment was: 
 
“I do personally feel I should have been involved a lot sooner. And I know they didn’t want 
to involve too many people but actually …. we were quite crucial in it all, and especially 
because of local knowledge, so I did feel …… we didn’t have enough preparation for it and 
then there was a lot of pressure to get …recruitment up ….” 
 
Research network support in terms of research nurse time, and additional training would have 
increased the CNSs’ understanding of the protocol.  
 
The participants that were recruited into the study had a mean age of 59.8 years and had received 
their initial diagnosis a little over five months (mean=159 days) prior to randomisation. Eligibility 
criteria stipulated at baseline were that the participant must be within three months of their last 
treatment and this was confirmed by the mean of 84 days post treatment found in the study sample. 
One person was 109 days from their end of treatment due to unforeseen appointment rescheduling 
but with Chief Investigator agreement this person was included within the study. The majority of 
participants (71%) had treatment for endometrial cancer (21% ovarian, 8% cervical, none had vulval 
carcinoma). All patients received surgery as part of their treatment, 46% combined this with either 
chemotherapy or radiotherapy (see Table 1 for further details). 
 
Completion rates of the QoL and wellbeing measures were evaluated based on the final scores for the 
measures collected within the study. Four outcomes (nausea and vomiting subscale, appetite loss 
subscale, diarrhoea subscale and EQ-5D-3L index) had one data point missing at baseline, giving a 
minimum completion at the time point of 96%. All outcomes three- and six-month follow-up achieved 
completion rates of 100%. 
 
Assumptions of normality were met based on scrutiny of distributions of composite variables, single 
or dual item variables are treated as categorical. The appropriate descriptive statistics (means and 
standard deviation for normally distributed subscales and the modal class for the remaining subscales) 
of the EORTC-QLQ-C30 are presented in Table 2. Differences were noted at baseline between the two 
treatment allocations on several outcome measures outlining the importance of baseline adjustments 
where possible. For all subscales, the OPCAT-G intervention had equal or better scores at six-month 
follow-up compared to the standard care arm of the study.  
 
ANCOVA models on the four appropriate subscales have evaluated all effect sizes in a positive 
direction for the OPCAT-G intervention (Table 2). The largest effect was identified on the physical 
functioning subscale but the QoL and fatigue subscales also identified changes of four points. All 
effects have large confidence intervals due to the small sample size and so should be taken as 
indicative only. 
 
For the purposes of the economic analysis, this feasibility took an NHS and voluntary sector 
perspective. An exploratory cost consequences analysis was conducted on the participants that had 
complete cost and outcome data (n=21: 10 in Intervention arm, 11 in Control arm). The frequency of 
contacts with primary and secondary care health services and other cancer services use at six-months 
post-baseline can be found in supplementary material table 1. Results show that there is no significant 
difference between the two groups in the frequency of contacts with primary care and other cancer 
services. For secondary care, no significant difference between groups was shown for all secondary 
care service contacts except telephone contacts with the CNSs in which the OPCAT-G intervention 
group had, on average, higher usage (mean frequency=1.70) than the standard care group (mean 
frequency=0.27). 
 
Table 3 shows intervention delivery cost details for the OPCAT-G intervention and standard care. 
Results show that mean intervention cost per patient for delivering the OPCAT-G intervention and 
standard care was £76.02 and £52.99 per patient, respectively; a difference of £23.03. Table 4 shows 
mean costs of all contacts with NHS primary and secondary care services and other cancer services by 
participants in the OPCAT-G intervention and standard care groups over the six-month follow-up 
period. These included primary care consultations, secondary care consultations and other cancer 
services (e.g. voluntary sector support). Results show that the mean total cost per patient was £388.84 
(SD=£320.11) for the OPCAT-G intervention group and £415.44 (SD=£329.08) for the standard care 
group over the six-month follow up period. The difference in mean total cost between the two groups 
was -£26.60 (bootstrapped 95% confidence interval (CI): -£290.37 to £240.42). Although this 
difference is not statistically significant, the mean total costs of service use were lower in the OPCAT-
G intervention group. 
 
Table 5 shows participants in the OPCAT-G intervention group had, on average, a smaller quality of 
life years (QALY) gain compared to participants in the standard care group with a mean difference of 
-0.06 QALYs (bootstrapped 95% CI: -0.18 to 0.05); this difference was not statistically significant. Table 
5 shows change in mean ICECAP-A score between baseline and six-months post baseline for 
participants in the intervention group (mean=0.01 (SD=0.09)) and standard care group (mean=-0.04 
(SD=0.16)). The difference in mean change scores between the two groups was 0.05 (bootstrapped 
95% CI: -0.05 to 0.16) and this difference was not statistically significant. 
 
Two adverse events were reported during the trial, one relapse and one pulmonary embolism, neither 
were deemed to be trial related and both continued in the trial. 
 
 
  
Discussion 
We have demonstrated the feasibility of TOPCAT-G as a trial in terms of acceptable eligibility, 
recruitment and retention rates related to rates defined a priori. Additionally, all outcome measures 
were completed to a high standard and there is no concern about including these in a future 
definitive RCT.  
 
The trial had the potential to include a range of difference tumour types; however, the sample 
recruited was highly biased towards early stage endometrial cancer patients. There were no vulval 
cancer cases recruited during the limited recruitment window. A future study needs to ensure a 
sufficiently representative population of gynaecological patients to enhance the generalisability of 
findings. The process evaluation showed that involvement of the local CNSs is important for their 
recruitment with training and regular contact including site visits from the central TOPCAT-G 
research team members. There were implications for the CNSs in terms of screening clinics to 
increase the number of patients approached and then in terms of conducting the actual 
intervention, as telephone reviews had not previously been conducted at two of the sites prior to 
the trial. The study did impact on the CNS work and they felt they had not been consulted about it 
soon enough. 
These issues could have been resolved with a formal ‘training day’ explaining the aims and 
objectives as well as the work required rather than an informal discussion. It is essential for those 
involved to understand the rationale of why the study is being conducted. For the full trial, sites will 
need to go through a feasibility check to open and see if they have the resources to take part in 
terms of network support and CNS involvement. The CNSs would need to feel at ease conducting the 
intervention and would need to be consulted and involved early on in assessing suitability as a site 
for trial recruitment. 
 
The current study may have been limited by requiring recruitment within three months 
following the end of treatment. A participant was included from outside the recruitment 
window. With appointment cancellations and changes, this proved a strain for the nurses to 
ensure this time window was met. From a clinical point of view, this timeline was not 
essential. It is, however, important that treatment be completed in order for the ‘follow-up 
phase’ of care to begin and so recruitment should be as soon as is reasonable after completing 
treatment to eliminate any treatment related problems experienced at this time requiring 
specialist help [5]. This recruitment window will be re-considered within a full trial and the 
most appropriate time limits allocated to the inclusion criteria.  
 
One major operational issue for the study was finding appropriate dedicated time for each of the CNSs 
to complete their telephone follow-up interviews with the participants. Gaining information on issues 
such as this is a vital part of the shaping the design of a future RCT.  Each telephone follow-up took on 
average 34.7 minutes for the CNSs to complete. 
 
The mean overall total time spent by CNSs for delivering the nurse-led intervention (95.2 minutes) 
was shown to be higher than the average overall total time spent by outpatient doctors for delivering 
the routine clinic follow-up (23.6 minutes). This difference was perhaps due to all time spent by 
outpatient doctors not being collected in this feasibility trial, leading to a possible underestimation of 
outpatient doctor time. Additional time was required for doctors looking through patients’ hospital 
notes before and after seeing patients. For consistency and accuracy, the preparation, contact time 
and subsequent time spent by outpatient doctors should be recorded within a future definitive RCT.  
Despite this, the exploratory cost consequences analysis results demonstrate that the intervention 
group had a mean total service use cost £27 per patient (bootstrapped 95%CI: -£290 to £240) lower 
than the standard care group.  
 
In conclusion the feasibility trial demonstrated that the study protocol demonstrated satisfactory 
eligibility, recruitment and retention rates as well as satisfactory outcome measure completion. 
Analyses of outcome measures indicated positive changes in QoL and wellbeing within the OPCAT-G 
group; exploratory cost consequence analysis indicated that the nurse-led intervention had a mean 
total service use cost £27 per patient lower than the standard care group. 
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 Figure 1: CONSORT diagram for the TOPCAT-G feasibility trial 
 
  
Table 1: Descriptive statistics of the demographic variables (n=24) 
Characteristic 
Overall 
Mean (SD); range 
Standard Care 
Mean (SD); range 
OPCAT-G 
Intervention 
Mean (SD); range 
Age (years) 
59.8 (11.2);  
40-77 
60.0 (11.9);  
42-77 
59.5 (11.1);  
40-75 
Time from diagnosis (days) 
158.5 (58.3);  
46-287 
154.8 (75.2);  
46-287 
162.3 (37.9);  
118-230 
Time from last treatment (days) 
84.3 (13.4);  
46-109 
80.1 (14.1);  
46-97 
88.5 (11.7);  
66-109 
 
Overall  
N (%) 
Standard Care 
 N (%) 
OPCAT-G 
Intervention 
N (%) 
Cancer    
Endometrial (Uterine) 17 (71%) 8 (67%) 9 (75%) 
Ovarian 5 (21%) 4 (33%) 1 (8%) 
Cervical 2 (8%) 0 (0%) 2(17%) 
Uterine Staging    
IA 10 (59%) 5 (63%) 5 (56%) 
IB 6 (35%) 2 (25%) 4 (44%) 
II 1 (6%) 1 (12%) 0 (0%) 
Ovary Staging    
IA 2 (40%) 2 (50%) 0 (0%) 
IIIC 3 (60%) 2 (50%) 1 (100%) 
Cervical Staging    
IA1 1 (50%) 0 (0%) 1 (50%) 
IB1 1 (50%) 0 (0%) 1 (50%) 
Treatment    
Surgery 13 (54%) 7 (58%) 6 (50%) 
Combination Therapy 11 (46%) 5 (42%) 6 (50%) 
Combination Therapy:    
Surgery & Chemo 3 (27%) 2 (40%) 1 (17%) 
Surgery & Radiotherapy 8 (73%) 3 (60%) 5 (83%) 
Comorbidities    
Diabetes 1 (4%) 0 (0%) 1 (8%) 
Cardiac Disease 1 (4%) 0 (0%) 1 (8%) 
Musculoskeletal 1 (4%) 1 (8%) 0 (0%) 
Hypertension 1 (4%) 0 (0%) 1 (8%) 
Skin Conditions 1 (4%) 0 (0%) 1 (8%) 
Other 7 (29%) 3 (25%) 4 (33%) 
Note: Higher scores represent higher/healthier levels of functioning of QoL. Subscales with * indicate reverse scoring where higher scores represent higher 
levels of the associated problem 
Table 2: Descriptive statistics of the EORTC QLQ-C30 subscales, the adjusted mean difference from ANCOVA analysis and related effect size.  
EORTC QLQ-C30 
Subscales 
Baseline 3-Month Follow-up 6-Month Follow-up 
Adjusted 
mean 
difference at 
6 month 
follow-up 
Cohen’s D Effect 
Size (95% CI) 
Standard  
Care 
OPCAT-G 
Intervention 
Standard  
Care 
OPCAT-G 
Intervention 
Standard  
Care 
OPCAT-G 
Intervention 
N=12 N=12 N=12 N=12 N=12 N=11 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Global Health Scale/QoL 70.1 (16.7) 63.2 (20.6) 68.1 (27.4) 63.8 (17.2) 67.3 (26.8) 68.2 (18.9) 4.2 0.20 (-0.62, 1.02) 
Physical functioning 83.3 (14.4) 73.9 (16.8) 81.0 (21.2) 75.0 (19.0) 76.9 (23.5) 84.3 (12.8) 14.3 0.98 (0.11, 1.84) 
Emotional functioning 72.3 (22.3) 84 (20.0) 81.3 (17.7) 71.5 (26.9) 68.1 (21.5) 80.3 (25.2) 1.6 0.10 (-0.72, 0.92) 
Fatigue* 35.2 (20.8) 36.9 (24.0) 34.2 (28.7) 42.5 (25.6) 36.0 (31.2) 33.2 (22.9) -4.1 -0.20 (-1.02, 0.62) 
 Modal Class Modal Class Modal Class Modal Class Modal Class Modal Class   
Role functioning 100 100 100 67 100 100   
Cognitive functioning 100 100 83 100 83 100   
Social functioning 100 100 100 100 100 100   
Nausea and vomiting* 0 0 0 0 0 0   
Pain* 0 0 0 0 & 17 0 0   
Dyspnoea* 0 33 0 33 0 0   
Insomnia* 33 0 33 33 67 33   
Appetite loss* 0 0 0 0 & 33 0 0   
Constipation* 0 0 0 33 0 0   
Diarrhoea* 0 0 0 0 0 0   
Financial difficulties* 0 0 0 0 0 0   
Table 3: Mean intervention delivery cost per patient for delivering intervention in the intervention group and standard care in the control group 
 Quantity Unit cost (£) Cost (£) Remarks 
INTERVENTION GROUP     
(1) Intervention Patient Information Booklet     
(1.1) Papers for printing one booklet (Total papers) 8 papers 0.01 0.08 
£5 for 500 sheets in a ream; Calc. 
£5/500= £0.01 per paper 
(1.2) Ink for colour printing one booklet (Total pages) 14 pages 0.25 3.50 
Bangor University's A4 Colour 
printing cost @ 25p per A4 side 
(1.3) Average time spent by Clinical Nurse Specialist (CNS) 
explaining the booklet to patient in clinic (Mean total mins) 
14 minutes 0.73 10.27  
(2) Intervention Needs Assessment documents     
(2.1) Macmillan Concerns Checklist form 1 0.00 0.00 Free of charge 
(2.2) Papers for printing CancerCAN-22 and Distress Thermometer 
(Total papers) 
3 papers 0.01 0.03 
£5 for 500 sheets in a ream; Calc. 
£5/500= £0.01 per paper 
(2.3) Ink for colour printing CancerCAN-22 and Distress 
Thermometer (Total pages) 
6 pages 0.25 1.50 
Bangor University's A4 Colour 
printing cost @ 25p per A4 side 
(2.4) Postage for patient to post back their needs assessment 
forms to CNS (2 times second class postage over the 6-month 
study period) 
(Total stamps cost (£)) 
2 stamps 0.55 1.10 2nd class stamp cost in 2016 
(3) Average total time spent (in minutes) by CNS for outside client contact 
(e.g. planning time spent by CNS looking through patient's hospital notes 
before a telephone follow-up) for two telephone follow-up received by a 
patient over the 6-month study period 
46.50 
minutes 
0.73 34.10  
(4) Average total non-face-to-face (phone) contact time (in minutes) spent 
by CNS for two telephone follow-up received by a patient over the 6-
month study period 
34.70 
minutes 
0.73 25.45  
(5) Average grand total time spent by CNS over 6-month study period 
[(1.3)+(3)+(4)] 
95.20 
minutes 
0.73 69.81  
(6) Grand total of intervention cost (£) 
[(1.1)+(1.2)+(1.3)+(2.1)+(2.2)+(2.3)+(2.4)+(3)+(4)] 
  76.02  
CONTROL GROUP     
(7) Average total face-to-face contact time (in minutes) of two clinic 
follow-up over 6-month study period, spent by consultant with a patient in 
clinic  
23.55 
minutes 
2.25 52.99  
(8) Grand total of control group cost (£)    52.99  
(10) Difference in grand total cost between intervention and control 
group (£) [(6)-(8)] 
  23.03  
 
Table 4: Cost of primary and secondary care health services and other cancer services use by participants 
(n=21) (£) over the 6-month study period*¥ 
 
Nurse-led 
 (n=10) 
Mean  (SD) in £ 
Standard Care 
(n=11) 
Mean (SD) in £ 
Mean difference in £ 
(95% CI 
bootstrapped) 
NHS PRIMARY CARE AND OTHER CANCER SERVICES 
GP consultations:    
Surgery 36.00 (61.19) 49.09 (85.61) -13.09 
Home visit 0.00 (0.00) 0.00 (0.00) 0.00 
Telephone 5.54 (17.51) 10.07 (33.40) -4.53 
Total (Surgery, home visit and telephone) 41.54 (70.26) 59.16 (110.19) -17.62 
Practice nurse consultations:    
Surgery 0.00 (0.00) 8.08 (17.28) -8.08 
Home visit 0.00 (0.00) 0.00 (0.00) 0.00 
Telephone 0.00 (0.00) 0.39 (1.30) -0.39 
Total (Surgery, home visit and telephone) 0.00 (0.00) 8.47 (17.67) -8.47 
Counsellor:    
Clinic 6.30 (19.92) 0.00 (0.00) 6.30 
Home visit 0.00 (0.00) 0.00 (0.00) 0.00 
Telephone 0.00 (0.00) 0.00 (0.00) 0.00 
Total (Surgery, home visit and telephone) 6.30 (19.92) 0.00 (0.00) 6.30 
Physiotherapist:    
Clinic 6.40 (13.49) 0.00 (0.00) 6.40 
Home visit 0.00 (0.00) 0.00 (0.00) 0.00 
Telephone 1.60 (5.06) 0.00 (0.00) 1.60 
Total (Surgery, home visit and telephone) 8.00 (17.28) 0.00 (0.00) 8.00 
Other cancer services e.g. charity:   
Clinic 4.50 (14.23) 0.00 (0.00) 4.50 
Home visit 0.00 (0.00) 0.00 (0.00) 0.00 
Telephone 16.80 (53.13) 0.00 (0.00) 16.80 
Total (Surgery, home visit and telephone) 21.30 (67.36) 0.00 (0.00) 21.30 
Total NHS primary care and other cancer 
services costs 
77.14 (147.85) 67.63 (121.90) 
9.51  
(-97.03 to 127.12) 
NHS SECONDARY CARE    
Consultant:    
Face-to-face 163.00 (153.68) 237.09 (168.82) -74.09 
Telephone 32.00 (67.46) 0.00 (0.00) 32.00 
Total (face-to-face and telephone) 195.00 (199.40) 237.09 (168.82) -42.09 
Gynaecological cancer specialist nurse:   
Face-to-face 7.70 (10.44) 7.00 (10.17) 0.70 
Telephone 7.48 (5.10) 1.20 (2.06) 6.28 
Total (face-to-face and telephone) 15.18 (12.11) 8.20 (11.31) 6.98 
Accident and emergency:    
Face-to-face 15.40 (48.70) 28.00 (92.87) -12.60 
Telephone 0.00 (0.00) 0.00 (0.00) 0.00 
Total (face-to-face and telephone) 15.40 (48.70) 28.00 (92.87) -12.60 
Other hospital services:    
Face-to-face 5.90 (13.76) 13.91 (46.13) -8.01 
Telephone 4.20 (13.28) 7.64 (25.33) -3.44 
Total (face-to-face and telephone) 10.10 (26.51) 21.55 (50.36) -11.45 
Total NHS secondary care costs 235.68 (235.71) 294.84 (256.31) 
-59.16  
(-262.76 to 138.74) 
Total NHS primary and secondary care and 
other cancer services sector costs 
312.82 (309.87) 362.47 (317.93) 
-49.65  
(-300.99 to 197.14) 
Intervention cost (Nurse-led intervention / 
standard care) 
76.02 (27.55) 52.99 (23.99) 23.03 
Total cost 388.84 (320.11) 415.44 (329.08) 
-26.60  
(-290.37 to 240.42) 
NHS: National Health Service 
*Cost year 2015/16 
¥NHS costs including salary, employers’ costs, overheads and capital costs. 
Note: All other variables collected had no associated costs and so were not included in the table, these all relate to 
clinic/surgery, home visits and telephone calls unless otherwise stated: GP out-of-hours consultations, district nurse 
consultations,  community nurse consultation, NHS Direct Wales (telephone),  psychologist,  occupational health 
therapist,  dietician, social worker, social services support worker. 
Table 5: Participants self-reported EQ-5D-3L index scores, mean QALYs and incremental mean QALYs and ICECAP-A scores with mean change 
of scores between groups at 6-month post-baseline by group in the TOPCAT-G feasibility trial (n=21) 
Measure 
Nurse-led (n = 10) 
Mean (SD) 
Standard Care (n = 11) 
Mean (SD) 
Incremental mean 
QALYs between groups® 
 (bootstrapped 95% CI) 
Baseline 
 
3 month 
follow-up 
6 month 
follow-up 
QALY over 6 
months 
Baseline 
 
3 month 
follow-up 
6 month 
follow-up 
QALY over 6 
months 
EQ-5D-3L 
index score 
0.64 
(0.28) 
0.68 
(0.36) 
0.76 
(0.29) 
0.34 
(0.14) 
0.78 
(0.26) 
0.39 
(0.14) 
0.80 
(0.37) 
0.41 
(0.14) 
-0.06 
(-0.18 to 0.05) 
 
Baseline 
3 month 
follow-up 
6 month 
follow-up 
Change in mean 
ICECAP-A score 
between baseline 
and 6 months® 
Baseline 
3 month 
follow-up 
6 month 
follow-up 
Change in mean 
ICECAP-A score 
between baseline 
and 6 months® 
Difference in mean 
ICECAP-A change scores 
between groups¥ 
(bootstrapped 95% CI) 
ICECAP-A 
index scores 
0.82 
(0.20) 
0.70 
(0.30) 
0.83 
(0.22) 
0.01 
(0.09) 
0.89 
(0.13) 
0.93 
(0.13) 
0.84 
(0.21) 
-0.04 
(0.16) 
0.05 
(-0.05 to 0.16) 
®Incremental mean QALYs between groups = mean QALYs for nurse-led group minus mean QALYs for standard care group   
®Change in mean ICECAP-A score = (Mean ICECAP-A score at 6 months) minus (Mean ICECAP-A score at baseline) 
¥Difference in mean ICECAP-A change scores between groups = (Mean change ICECAP-A score for nurse-led group) minus (Mean change 
ICECAP-A score for standard care group)
  
 
